- Home
- DSM vs AMRN Comparison
DSM vs AMRN Comparison
Compare DSM & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$16.16
Company Overview
Basic Information| Metric | DSM | AMRN |
|---|---|---|
| Founded | 1989 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.5M | 339.8M |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | DSM | AMRN |
|---|---|---|
| Price | $6.18 | $16.16 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 161.7K | 95.1K |
| Earning Date | 01-01-0001 | 10-29-2025 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $226,733,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.69 | $7.08 |
| 52 Week High | $6.05 | $20.90 |
Technical Indicators
Market Signals| Indicator | DSM | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 67.37 | 64.25 |
| Support Level | $6.00 | $13.12 |
| Resistance Level | $6.05 | $14.33 |
| Average True Range (ATR) | 0.06 | 0.72 |
| MACD | 0.01 | 0.35 |
| Stochastic Oscillator | 100.00 | 84.78 |
Price Performance
Historical Comparison DSM
AMRN
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.